Show simple item record

An Anti-hTNF-α Variable New Antigen Receptor Format Demonstrates Superior in vivo Preclinical Efficacy to Humira® in a Transgenic Mouse Autoimmune Polyarthritis Disease Model

dc.contributor.authorUbah, Obinna C.
dc.contributor.authorSteven, John
dc.contributor.authorPorter, Andrew J.
dc.contributor.authorBarelle, Caroline J.
dc.date.accessioned2019-03-22T11:30:06Z
dc.date.available2019-03-22T11:30:06Z
dc.date.issued2019-03
dc.identifier.citationUbah , O C , Steven , J , Porter , A J & Barelle , C J 2019 , ' An Anti-hTNF-α Variable New Antigen Receptor Format Demonstrates Superior in vivo Preclinical Efficacy to Humira® in a Transgenic Mouse Autoimmune Polyarthritis Disease Model ' , Frontiers in Immunology , vol. 10 , 526 . https://doi.org/10.3389/fimmu.2019.00526en
dc.identifier.issn1664-3224
dc.identifier.otherPURE: 142500674
dc.identifier.otherPURE UUID: 918010a8-54aa-4fca-8682-1a04e1402bd8
dc.identifier.otherRIS: urn:F2D6899978E05B8509B07A2EE5FEBA44
dc.identifier.otherScopus: 85064721344
dc.identifier.otherMendeley: 12816d3c-6ded-3da5-bca3-d680c2133405
dc.identifier.otherWOS: 000461990600001
dc.identifier.urihttp://hdl.handle.net/2164/12078
dc.descriptionFunding The Biotechnology and Biological Sciences Research Council (BB/K010905/1), Scottish Enterprise (VNAR_001 (2012), Innovate UK (102865). Acknowledgments The authors wish to acknowledge the funding support for this work from Scottish Enterprise (SE), the Biotechnology and Biological Sciences Research Council (BBSRC), and Innovate UK.en
dc.format.extent12
dc.language.isoeng
dc.relation.ispartofFrontiers in Immunologyen
dc.rights© 2019 Ubah, Steven, Porter and Barelle. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. https://creativecommons.org/licenses/by/4.0/en
dc.subjectvariable new antigen receptors (VNARs)en
dc.subjectchronic inflammationen
dc.subjectshark IgNARen
dc.subjectanti-TNF biologicsen
dc.subjectrheumatoid arthritisen
dc.subjectautoimmune diseaseen
dc.subjectTNF-alphaen
dc.subjectRHEUMATOID-ARTHRITISen
dc.subjectADALIMUMABen
dc.subjectTHERAPEUTIC ANTIBODIESen
dc.subjectKNOCKOUT MICEen
dc.subjectDOSE-ESCALATIONen
dc.subjectMURINE MODELen
dc.subjectIMMUNOGENICITYen
dc.subjectTUMOR-NECROSIS-FACTORen
dc.subjectTRANSMEMBRANE TNF-ALPHAen
dc.subjectMONOCLONAL-ANTIBODIESen
dc.subjectR Medicine (General)en
dc.subjectImmunology and Allergyen
dc.subjectImmunologyen
dc.subjectInnovate UKen
dc.subject102865en
dc.subjectBiotechnology and Biological Sciences Research Council (BBSRC)en
dc.subjectBB/K010905/1en
dc.subjectOtheren
dc.subjectVNAR_001 (2012)en
dc.subject.lccR1en
dc.titleAn Anti-hTNF-α Variable New Antigen Receptor Format Demonstrates Superior in vivo Preclinical Efficacy to Humira® in a Transgenic Mouse Autoimmune Polyarthritis Disease Modelen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Medical Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Institute of Medical Sciencesen
dc.description.statusPeer revieweden
dc.description.versionPublisher PDFen
dc.identifier.doihttps://doi.org/10.3389/fimmu.2019.00526
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85064721344&partnerID=8YFLogxKen
dc.identifier.urlhttps://www.frontiersin.org/article/10.3389/fimmu.2019.00526/fullen
dc.identifier.urlhttp://www.mendeley.com/research/antihtnf%CE%B1-variable-new-antigen-receptor-format-demonstrates-superior-vivo-preclinical-efficacy-humiren
dc.identifier.vol10en


Files in this item

Thumbnail
Name:
fimmu_10_00526.pdf
Size:
2.540Mb
Format:
PDF
View/Open

This item appears in the following Collection(s)

Show simple item record